Syros Pharmaceuticals (SYRS) Earns Daily Media Impact Rating of 0.12
Media stories about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5584591099068 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Brokerages Expect Syros Pharmaceuticals, Inc. (SYRS) Will Announce Earnings of -$0.53 Per Share (americanbankingnews.com)
- Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference (finance.yahoo.com)
- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Sees Significantly Higher Trading Volume (highlightpress.com)
- Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : September 1, 2017 (finance.yahoo.com)
A number of equities analysts have recently weighed in on SYRS shares. Cann reaffirmed a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Oppenheimer Holdings, Inc. set a $28.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Syros Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $20.81.
Syros Pharmaceuticals (NASDAQ SYRS) traded down 4.97% during trading on Wednesday, reaching $17.39. 246,231 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $20.72 and a 200-day moving average price of $16.57. The firm’s market cap is $456.66 million. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, analysts forecast that Syros Pharmaceuticals will post ($2.09) earnings per share for the current fiscal year.
In other Syros Pharmaceuticals news, Director Richard A. Young sold 3,282 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the sale, the director now directly owns 423,383 shares in the company, valued at approximately $9,352,530.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric R. Olson sold 12,500 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the sale, the insider now owns 12,500 shares in the company, valued at $273,125. The disclosure for this sale can be found here. Insiders sold a total of 21,564 shares of company stock worth $476,803 over the last quarter.
COPYRIGHT VIOLATION NOTICE: “Syros Pharmaceuticals (SYRS) Earns Daily Media Impact Rating of 0.12” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/06/syros-pharmaceuticals-syrs-earns-daily-media-impact-rating-of-0-12.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.